Literature DB >> 24694745

Maximal exercise testing of men with prostate cancer being treated with androgen deprivation therapy.

Bradley A Wall1, Daniel A Galvão, Naeem Fatehee, Dennis R Taaffe, Nigel Spry, David Joseph, Robert U Newton.   

Abstract

UNLABELLED: Exercise is being increasingly established as a key adjuvant therapy in clinical oncology. As research has demonstrated the beneficial effect of exercise for cancer management, a growing number of patients with cancer are undertaking structured exercise programs.
PURPOSE: This study aimed to determine the safety and feasibility of formal exercise testing in clinical settings as it is becoming increasingly used as a screening tool and for exercise prescription purposes.
METHODS: One hundred and twelve patients with prostate cancer undergoing androgen deprivation therapy (ADT) took part in a physician-supervised multistage maximal stress test (Bruce protocol). Sixty patients had been on ADT for <3 months (acute), whereas 52 had been on ADT for >3 months (chronic).
RESULTS: Of these men, 85% were able to meet the criteria for the attainment of V˙O2max, whereas three positive tests (3.2%) were observed. The three participants who recorded a positive stress test underwent further medical examination and were subsequently cleared of clinically significant cardiovascular disease. Apart from the relatively low V˙O2max (24.7 ± 6.0 mL·kg·min, 10th-15th percentile), compared with normative data in healthy age-matched controls, the cardiovascular response to exercise was similar in this cancer population. Moreover, treatment duration did not seem to influence cardiovascular responses to exercise. This early evidence suggests that risk of adverse events during maximal exercise testing is relatively low in this population and certainly no higher than that in ages-matched, apparently healthy individuals.
CONCLUSIONS: Maximal exercise testing was demonstrated to be feasible and safe, providing a direct assessment of V˙O2max. The relatively low number of positive tests in this study suggests that the risk of adverse events is relatively low in this population and certainly no higher than that in age-matched, apparently healthy individuals.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24694745     DOI: 10.1249/MSS.0000000000000353

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  10 in total

1.  Exercise Improves Physical Function and Mental Health of Brain Cancer Survivors: Two Exploratory Case Studies.

Authors:  Gregory T Levin; Kenneth M Greenwood; Favil Singh; Daphne Tsoi; Robert U Newton
Journal:  Integr Cancer Ther       Date:  2015-08-14       Impact factor: 3.279

2.  Multimodal exercise ameliorates exercise responses and body composition in head and neck cancer patients receiving chemotherapy.

Authors:  Chia-Jui Yen; Ching-Hsia Hung; Chung-Lan Kao; Wei-Ming Tsai; Shih-Hung Chan; Hui-Ching Cheng; Wan-Ting Jheng; Yan-Jhen Lu; Kun-Ling Tsai
Journal:  Support Care Cancer       Date:  2019-04-04       Impact factor: 3.603

3.  Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial.

Authors:  Renée Bultijnck; Benedicte Deforche; Noëmi Borrey; Jörgen Van Bauwel; Maarten Lievens; Elke Rammant; Valérie Fonteyne; Karel Decaestecker; Adelheid Steyaert; Nicolaas Lumen; Piet Ost
Journal:  World J Urol       Date:  2020-02-01       Impact factor: 4.226

4.  Effect of Exercise Training on Exercise Tolerance and Level of Oxidative Stress for Head and Neck Cancer Patients Following Chemotherapy.

Authors:  Chia-Jui Yen; Ching-Hsia Hung; Wei-Ming Tsai; Hui-Ching Cheng; Hsin-Lun Yang; Yan-Jhen Lu; Kun-Ling Tsai
Journal:  Front Oncol       Date:  2020-08-18       Impact factor: 6.244

5.  The Phys-Can observational study: adjuvant chemotherapy is associated with a reduction whereas physical activity level before start of treatment is associated with maintenance of maximal oxygen uptake in patients with cancer.

Authors:  Tor Helge Wiestad; Truls Raastad; Karin Nordin; Helena Igelström; Anna Henriksson; Ingrid Demmelmaier; Sveinung Berntsen
Journal:  BMC Sports Sci Med Rehabil       Date:  2020-09-03

6.  Criteria for the determination of maximal oxygen uptake in patients newly diagnosed with cancer: Baseline data from the randomized controlled trial of physical training and cancer (Phys-Can).

Authors:  Ann Christin Helgesen Bjørke; Truls Raastad; Sveinung Berntsen
Journal:  PLoS One       Date:  2020-06-11       Impact factor: 3.240

7.  Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Jingyi Gong; David Payne; Jesse Caron; Camden P Bay; Bradley A McGregor; Jon Hainer; Ann H Partridge; Tomas G Neilan; Marcelo Di Carli; Anju Nohria; John D Groarke
Journal:  JACC CardioOncol       Date:  2020-11-17

Review 8.  Cardiovascular effects of hormone therapy for prostate cancer.

Authors:  Jason F Lester; Malcolm D Mason
Journal:  Drug Healthc Patient Saf       Date:  2015-07-23

9.  The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada.

Authors:  Margot K Davis; Jennifer L Rajala; Scott Tyldesley; Tom Pickles; Sean A Virani
Journal:  J Oncol       Date:  2015-08-02       Impact factor: 4.375

10.  Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation.

Authors:  Bradley A Wall; Daniel A Galvão; Naeem Fatehee; Dennis R Taaffe; Nigel Spry; David Joseph; Robert U Newton
Journal:  Adv Urol       Date:  2015-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.